Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-cell lymphomas and le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Leukemia
• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CLIC-2201

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: B-Cell Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Status: RECRUITING